Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) Enterprise Value (2022 - 2026)

Day One Biopharmaceuticals (DAWN) has disclosed Enterprise Value for 4 consecutive years, with -$441.1 million as the latest value for Q4 2025.

  • For Q4 2025, Enterprise Value rose 17.04% year-over-year to -$441.1 million; the TTM value through Dec 2025 reached -$441.1 million, up 17.04%, while the annual FY2025 figure was -$441.1 million, 17.04% up from the prior year.
  • Enterprise Value was -$441.1 million for Q4 2025 at Day One Biopharmaceuticals, up from -$451.6 million in the prior quarter.
  • The five-year high for Enterprise Value was -$262.7 million in Q1 2022, with the low at -$558.4 million in Q3 2024.
  • Historically, Enterprise Value has averaged -$405.6 million across 4 years, with a median of -$397.2 million in 2022.
  • Biggest YoY gain for Enterprise Value was 19.13% in 2025; the steepest drop was 48.77% in 2025.
  • Over 4 years, Enterprise Value stood at -$342.3 million in 2022, then decreased by 7.03% to -$366.3 million in 2023, then tumbled by 45.14% to -$531.7 million in 2024, then rose by 17.04% to -$441.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$441.1 million in Q4 2025, -$451.6 million in Q3 2025, and -$453.1 million in Q2 2025.